About Ocular Therapeutix, Inc. - Common Stock (OCUL)
Ocular Therapeutics is a biotechnology company focused on developing innovative therapies for eye diseases and conditions. The company is primarily engaged in the research and development of unique drug delivery solutions that aim to improve the effectiveness and safety of treatments for various ocular diseases. Ocular Therapeutics leverages advanced technology platforms to create products that can provide sustained release of medication, enhancing patient compliance and outcomes. Their pipeline includes therapies targeting conditions such as retinal diseases and dry eye, positioning the company at the forefront of addressing significant unmet needs in the field of ophthalmology. Read More
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.
